Assessment of Neuroanatomical Endophenotypes of Autism Spectrum Disorder and Association with Characteristics of Individuals with Schizophrenia and the General Population
Gyujoon Hwang,Junhao Wen,Susan Sotardi,Edward S. Brodkin,Ganesh B. Chand,Dominic B. Dwyer,Guray Erus,Jimit Doshi,Pankhuri Singhal,Dhivya Srinivasan,Erdem Varol,Aristeidis Sotiras,Paola Dazzan,Rene S. S. Kahn,Hugo G. G. Schnack,Marcus V. V. Zanetti,Eva Meisenzahl,Geraldo F. F. Busatto,Benedicto Crespo-Facorro,Christos Pantelis,Stephen J. J. Wood,Chuanjun Zhuo,Russell T. T. Shinohara,Haochang Shou,Yong Fan,Adriana Di Martino,Nikolaos Koutsouleris,Raquel E. E. Gur,Ruben C. C. Gur,Theodore D. D. Satterthwaite,Daniel H. H. Wolf,Christos Davatzikos
DOI: https://doi.org/10.1001/jamapsychiatry.2023.0409
2023-01-01
JAMA Psychiatry
Abstract:ImportanceAutism spectrum disorder (ASD) is associated with significant clinical, neuroanatomical, and genetic heterogeneity that limits precision diagnostics and treatment.ObjectiveTo assess distinct neuroanatomical dimensions of ASD using novel semisupervised machine learning methods and to test whether the dimensions can serve as endophenotypes also in non-ASD populations.Design, Setting, and ParticipantsThis cross-sectional study used imaging data from the publicly available Autism Brain Imaging Data Exchange (ABIDE) repositories as the discovery cohort. The ABIDE sample included individuals diagnosed with ASD aged between 16 and 64 years and age- and sex-match typically developing individuals. Validation cohorts included individuals with schizophrenia from the Psychosis Heterogeneity Evaluated via Dimensional Neuroimaging (PHENOM) consortium and individuals from the UK Biobank to represent the general population. The multisite discovery cohort included 16 internationally distributed imaging sites. Analyses were performed between March 2021 and March 2022.Main Outcomes and MeasuresThe trained semisupervised heterogeneity through discriminative analysis models were tested for reproducibility using extensive cross-validations. It was then applied to individuals from the PHENOM and the UK Biobank. It was hypothesized that neuroanatomical dimensions of ASD would display distinct clinical and genetic profiles and would be prominent also in non-ASD populations.ResultsHeterogeneity through discriminative analysis models trained on T1-weighted brain magnetic resonance images of 307 individuals with ASD (mean [SD] age, 25.4 [9.8] years; 273 [88.9%] male) and 362 typically developing control individuals (mean [SD] age, 25.8 [8.9] years; 309 [85.4%] male) revealed that a 3-dimensional scheme was optimal to capture the ASD neuroanatomy. The first dimension (A1: aginglike) was associated with smaller brain volume, lower cognitive function, and aging-related genetic variants (FOXO3; Z = 4.65; P = 1.62 × 10-6). The second dimension (A2: schizophrenialike) was characterized by enlarged subcortical volumes, antipsychotic medication use (Cohen d = 0.65; false discovery rate-adjusted P = .048), partially overlapping genetic, neuroanatomical characteristics to schizophrenia (n = 307), and significant genetic heritability estimates in the general population (n = 14 786; mean [SD] h2, 0.71 [0.04]; P < 1 × 10-4). The third dimension (A3: typical ASD) was distinguished by enlarged cortical volumes, high nonverbal cognitive performance, and biological pathways implicating brain development and abnormal apoptosis (mean [SD] β, 0.83 [0.02]; P = 4.22 × 10-6).Conclusions and RelevanceThis cross-sectional study discovered 3-dimensional endophenotypic representation that may elucidate the heterogeneous neurobiological underpinnings of ASD to support precision diagnostics. The significant correspondence between A2 and schizophrenia indicates a possibility of identifying common biological mechanisms across the 2 mental health diagnoses.